M. Gezen Et Al. , "Development of novel compounds as Chemotherapeutic Drugs Targeting the MDM2-p53 Interaction," Molbiyokon’18, Biomedicine and Genome Center , İzmir, Turkey, pp.62, 2018
Gezen, M. Et Al. 2018. Development of novel compounds as Chemotherapeutic Drugs Targeting the MDM2-p53 Interaction. Molbiyokon’18, Biomedicine and Genome Center , (İzmir, Turkey), 62.
Gezen, M., Taşkıran, H., Tolay, N., KARALI, N. L., Erman, B., & Erman, B., (2018). Development of novel compounds as Chemotherapeutic Drugs Targeting the MDM2-p53 Interaction . Molbiyokon’18, Biomedicine and Genome Center (pp.62). İzmir, Turkey
Gezen, Melike Et Al. "Development of novel compounds as Chemotherapeutic Drugs Targeting the MDM2-p53 Interaction," Molbiyokon’18, Biomedicine and Genome Center, İzmir, Turkey, 2018
Gezen, Melike Et Al. "Development of novel compounds as Chemotherapeutic Drugs Targeting the MDM2-p53 Interaction." Molbiyokon’18, Biomedicine and Genome Center , İzmir, Turkey, pp.62, 2018
Gezen, M. Et Al. (2018) . "Development of novel compounds as Chemotherapeutic Drugs Targeting the MDM2-p53 Interaction." Molbiyokon’18, Biomedicine and Genome Center , İzmir, Turkey, p.62.
@conferencepaper{conferencepaper, author={Melike Gezen Et Al. }, title={Development of novel compounds as Chemotherapeutic Drugs Targeting the MDM2-p53 Interaction}, congress name={Molbiyokon’18, Biomedicine and Genome Center}, city={İzmir}, country={Turkey}, year={2018}, pages={62} }